This is the authors' abstract. We don't add key points for this paper.
Corneal transplant rejection poses a significant challenge for patients undergoing high-risk penetrating keratoplasty (HR-PKP). We systematically reviewed the literature to evaluate the efficacy of combining topical tacrolimus with steroids in reducing graft failure rates. A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Web of Science and CENTRAL/Cochrane databases were searched from inception to September 2024. Meta-analyses were conducted using weighted means, proportions and log odds ratios (OR) with a random-effects model. A two-tailed p-value of <0.05 was considered statistically significant. Out of 653 articles identified initially, five homogeneous comparative studies (n = 274 HR-PKP patients) were included. The tacrolimus-plus-steroids (n = 138) and steroids-alone (n = 136) groups were well-matched in baseline characteristics: weighted mean age (54.0 vs. 52.6 years, p = 0.90), sex distribution (p = 0.68), and underlying diagnoses with keratoconus being the most common (29.7% vs. 25.6%, p = 0.68). Follow-up durations were comparable as well (20.1 vs. 20.2 months, p = 0.98). After undergoing HR-PKP, patients in the tacrolimus-plus-steroids group showed significantly reduced graft failure odds by 75.0% (OR: 0.25 [95% CI: 0.13-0.43]) compared to patients in the steroids-alone group (p = 0.01). While preserving graft viability in HR-PKP patients remains challenging, adjunctive topical tacrolimus combined with steroids demonstrates a clinically meaningful reduction in graft failure risk. Larger long-term studies are warranted to validate these findings.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Qedair et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: